LeMaitre Vascular Inc (NASDAQ:LMAT) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $30.33.
Several equities research analysts recently commented on LMAT shares. Barrington Research set a $64.00 price objective on SurModics and gave the stock a “buy” rating in a report on Thursday, May 2nd. BidaskClub upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 20th. ValuEngine downgraded W&T Offshore from a “hold” rating to a “sell” rating in a report on Friday, April 26th. Finally, Zacks Investment Research downgraded GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th.
Several institutional investors have recently added to or reduced their stakes in LMAT. Copeland Capital Management LLC raised its stake in shares of LeMaitre Vascular by 150.7% in the second quarter. Copeland Capital Management LLC now owns 386,557 shares of the medical instruments supplier’s stock worth $10,816,000 after purchasing an additional 232,351 shares during the last quarter. Wasatch Advisors Inc. increased its holdings in shares of LeMaitre Vascular by 54.2% during the 1st quarter. Wasatch Advisors Inc. now owns 218,784 shares of the medical instruments supplier’s stock worth $6,782,000 after purchasing an additional 76,921 shares during the period. BlackRock Inc. increased its holdings in shares of LeMaitre Vascular by 2.2% during the 4th quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock worth $61,496,000 after purchasing an additional 56,161 shares during the period. Bridge City Capital LLC bought a new position in shares of LeMaitre Vascular during the 1st quarter worth about $1,352,000. Finally, Marshall Wace LLP increased its holdings in shares of LeMaitre Vascular by 36.0% during the 1st quarter. Marshall Wace LLP now owns 160,775 shares of the medical instruments supplier’s stock worth $4,984,000 after purchasing an additional 42,560 shares during the period. Institutional investors and hedge funds own 77.16% of the company’s stock.
NASDAQ LMAT traded down $0.48 during trading hours on Friday, hitting $30.42. The company’s stock had a trading volume of 65,933 shares, compared to its average volume of 125,349. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99. The stock has a 50 day moving average price of $27.50. The company has a market capitalization of $598.39 million, a P/E ratio of 36.21, a P/E/G ratio of 3.02 and a beta of 1.14.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). LeMaitre Vascular had a return on equity of 16.76% and a net margin of 20.92%. The business had revenue of $28.48 million during the quarter, compared to the consensus estimate of $27.94 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. LeMaitre Vascular’s quarterly revenue was up 9.6% compared to the same quarter last year. Equities analysts forecast that LeMaitre Vascular will post 0.83 EPS for the current fiscal year.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.